Pages that link to "Q38390695"
Jump to navigation
Jump to search
The following pages link to Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window (Q38390695):
Displaying 11 items.
- Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer (Q39069017) (← links)
- Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine (Q39429983) (← links)
- Effect of cardiopulmonary bypass on cytochrome P450 enzyme activity: implications for pharmacotherapy. (Q47288317) (← links)
- Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam. (Q47628234) (← links)
- Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of Drugs (Q50074569) (← links)
- Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. (Q52318495) (← links)
- Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label. (Q55080883) (← links)
- Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients. (Q55439721) (← links)
- A Semi-Physiologically Based Pharmacokinetic Model Describing the Altered Metabolism of Midazolam Due to Inflammation in Mice (Q89184496) (← links)
- Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies (Q93075017) (← links)
- Ribociclib Drug-Drug Interactions - Clinical Evaluations and PBPK Modeling to Guide Drug Labeling (Q96584157) (← links)